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430Objective: The roles of perioperative hyperglycemia and diabetes in the risk stratification of patients undergo-
ing coronary artery bypass graft surgery are unclear. The aim of this study is to explore the influence of
perioperative hyperglycemia on postoperative mortality.
Method: A prospective, observational study of 5050 patients undergoing cardiopulmonary bypass for coro-
nary artery bypass graft surgery at 70 international centers was conducted, with 7500 measured variables
per patient and outcomes adjudicated centrally. Postoperative blood glucose levels measured from the day
of surgery to postoperative day 3 were available for 4799 patients. Multivariable logistic regression was
used to determine the association of hyperglycemia with hospital mortality.
Results: A total of 164 patients died during hospitalization (3.2%). Mortality was significantly higher in the
diabetic population compared with the nondiabetic population (4.2% vs 2.9%; P¼ .02). In nondiabetic patients,
maximum postoperative blood glucose between 250 and 300 mg/dL (adjusted odds ratio, 2.56; 95% confidence
interval, 1.18–5.57; P ¼ .02) and maximum blood glucose of 300 mg/dL or greater (adjusted odds ratio, 2.74;
95% confidence interval, 1.22–6.16; P¼ .01), compared with maximum blood glucose less than 200mg/dL, and
postoperative insulin treatment (adjusted odds ratio, 2.04; 95% confidence interval, 1.12–3.70), were indepen-
dent risk factors for an increased risk of in-hospital mortality. In diabetic patients, hyperglycemia was not
associated with a higher mortality risk.
Conclusions: Postoperative hyperglycemia is associated with increased in-hospital mortality in nondiabetic
patients after coronary artery bypass graft surgery. In diabetic patients, hyperglycemia was not associated
with mortality. (J Thorac Cardiovasc Surg 2011;142:430-7)Supplemental material is available online.e Department of Anesthesia and Intensive Care,a Semmelweis University, Bu-
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The Journal of Thoracic and Cardiovascular SurgHyperglycemia commonly occurs in critically ill patients
and is associated with increased mortality and morbid-
ity.1,2 Postoperative control of hyperglycemia has been
shown to improve patient outcome in intensive care
units and after cardiac surgery.3,4 Hyperglycemia in
nondiabetic patients is related to stress hyperglycemia
and is a poor sign.5 In the era of percutaneous coronary in-
tervention, patients requiring coronary artery bypass graft
(CABG) surgery are older and sicker than in past years,
with approximately 20% being diabetic. Diabetes was
found to be an independent risk factor for in-hospital
and long-term mortality after cardiac surgery. Thus, a his-
tory of diabetes has been used for risk stratification in
cardiac surgery.6
After acute myocardial infarction, short-term mortality
was predicted by hyperglycemia at admission, whereas
long-term mortality was associated with diabetes.7 To eval-
uate the role of hyperglycemia on mortality after CABG
surgery, we investigated blood glucose levels using Multi-
center Study of Perioperative Ischemia Epidemiology II
data. We hypothesized that perioperative hyperglycemia is
associated with an increased mortality risk in both diabetic
and nondiabetic patients.ery c August 2011
Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
DOS ¼ day of surgery
OR ¼ odds ratio
POD3 ¼ postoperative day 3
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Study Design
The Multicenter Study of Perioperative Ischemia Epidemiology II is
a prospective, longitudinal, observational study that enrolled 5436 patients
with coronary artery disease refractory to medication, who were scheduled
for CABG surgery at 72 medical institutions among 17 countries in North
and South America, Europe, the Middle East, and Asia. After approval
from the institutional review board and written patient consent had been ob-
tained at each institution, 100 patients were selected for prospective enroll-
ment according to a systematic sampling scheme. Enrollment eligibility
criteria were as follows: scheduled to undergo CABG surgery with the use
of cardiopulmonary bypass (CPB), at least 18 years old, able to complete
the preoperative interview, and not enrolled in another study or clinical trial.
Enrollment commenced in November 1996 and ended in June 2000.
Study Data
For each enrolled patient, approximately 7500 variables were collected
from admission through discharge. Demographic, medical history, clinical,
laboratory, electrocardiographic, specialized testing, resource use, and ad-
verse outcome data were collected. Data were adjudicated centrally, with
all data for each patient examined for completeness and accuracy before
database closure on October 15, 2001.
Measurement of Outcomes
All outcomes were prespecified, defined by protocol, and determined by
investigators who were not aware of the subsequent planned analysis. Fatal
and nonfatal outcomes were classified as cardiac (myocardial infarction or
heart failure), cerebral (stroke or encephalopathy), renal (kidney dysfunc-
tion or failure), gastrointestinal (ischemia or infarction), or other (eg, ad-
verse events). Perioperative death was defined as any death occurring in
the hospital. Diabetic patients were defined as those with previously diag-
nosed disease at admission.
Clinical Care and Blood Glucose Measurements
Clinical decisions were not controlled by the study protocol. All patients
qualifying for enrollment within the prespecified 44-month enrollment pe-
riod were entered. Of the 5436 patients enrolled, 386 were excluded from
analysis because they chose to withdraw (32 patients); died before surgery
(2 patients); canceled or rescheduled surgery (97 patients); canceled CPB
with CABG surgery (132 patients); inadvertently enrolled in another study
(11 patients); had incomplete data (86 patients); had incomplete blood sam-
pling, shipping, or storage of blood (11 patients); or had incomplete data on
their diabetes status (15 patients). A total of 5050 patients remained in the
study. Maximum blood glucose levels were recorded before surgery (ad-
mission and preoperative), during surgery (before, during, and after
CPB), and postsurgery (at intensive care unit entry, remaining day of sur-
gery [DOS], postoperative days 1–4, maximum value after postoperative
day 4, and last day before discharge). Maximum blood glucose level at ad-
mission or preoperatively was categorized as 144 mg/dL or less and greaterThe Journal of Thoracic and Cathan 144 mg/dL.8 Maximum blood glucose level during surgery was used
as the intraoperative maximum blood glucose level. Maximum blood glu-
cose level between the remaining DOS and postoperative day 3 (POD3)
was used as the early postoperative maximum blood glucose level
(DOS–POD3 glucose maximum). Study patients were classified as having
good, moderate, poor, or very poor glucose control if the DOS–POD3 glu-
cose maximum was less than 200 mg/dL, 200 to less than 250 mg/dL, 250
to less than 300 mg/dL or 300 mg/dL or greater, respectively. The cutoff
points were defined on the basis of previous reports in the literature.9
Statistical Analysis
Descriptive statistics (mean, standard deviation, median, and interquar-
tile range) were calculated for all continuous variables, including blood
glucose levels. For categoric variables, a chi-square or Fisher exact test
was used to compare nondiabetic and diabetic patients; for continuous vari-
ables, a t test or Wilcoxon rank-sum test was applied.
Stratified analysis was conducted to examine the association between hy-
perglycemia and in-hospital mortality, controlling for the patients’ diabetic
histories and insulin treatment. Models were repeated using different defini-
tions of hyperglycemia, that is, early postoperativemaximum blood glucose
200 mg/dL or greater, 250 mg/dL or greater, or 300 mg/dL or greater.
Patients were evaluated as a group and then reanalyzed after grouping
by their history of diabetes. Diabetic patients were further subdivided
into 3 groups: insulin-treated diabetes, diet-controlled type 2 diabetes, or
oral antidiabetic-controlled type 2 diabetes. We developed a series of mul-
tivariable models to individually assess the independent effect of early
postoperative maximum blood glucose levels on mortality for the diabetic
patients and nondiabetic patients. In addition, the associations between hy-
perglycemia (DOS–POD3maximum blood glucose 250mg/dL) and pre-
dictors in nondiabetic patients were examined. Univariate associations
between postoperative mortality and a comprehensive list of risk factors
(preoperative demographic and medical characteristics, perioperative med-
ications, intraoperative variables, and perioperative laboratory values) were
investigated for each group using the chi-square test, Fisher exact test, and
logistic regression modeling. Risk factors significant at a nominal 2-sided
P value of .2 or less were then entered into multivariable logistic regression
models using a combination stepwise selection method; the model reten-
tion criterion was set at P less than .05. The calibration of the logistic
models was assessed using the Hosmer–Lemeshow goodness-of-fit test.
All statistical analyses were performed using SAS statistical software
(version 8.2, SAS Institute Inc, Cary, NC).RESULTS
Study Population
Thirty percent of patients had a history of diabetes (type 2
diabetes controlled by diet [5.1% of the whole population],
type 2 diabetes controlled with oral antidiabetics [17.4%],
or insulin-treated diabetes [7.5%]). Baseline demographics
and medical characteristics of all patients are listed in
Table 1.Mortality
A total of 164 of the 5050 patients (3.2%) died during
hospitalization in the study period. Eighty-one percent of
these deaths were preceded by vascular events: myocardial
infarction, congestive heart failure, stroke, or a combination
of these. Thirty-eight percent (63/164) of all deaths oc-
curred in patients with diabetes. Overall mortality rates
were 3.1%, 3.5%, and 6.4% in the diet-controlled, oralrdiovascular Surgery c Volume 142, Number 2 431
TABLE 1. Patient characteristics, preadmission comorbidities, preoperative chronic medication, and perioperative parameters: Nondiabetic and
diabetic patients*
Total population
(n ¼ 5050)
Nondiabetic
(n ¼ 3535)
Type 2 diabetes,
diet-controlled
(n ¼ 259)
Type 2 diabetes,
oral antidiabetic
medication (n ¼ 879)
Insulin–treated
diabetes
(n ¼ 377)
Characteristic no. (%) no. (%) No. (%) Py No. (%) Pz No. (%) Px
Age>70 y 1523 (30.2) 1099 (31.1) 91 (35.1) .17 235 (26.7) .01 98 (26.0) .04
Men 4018 (79.6) 2896 (81.9) 210 (81.1) .73 654 (74.4) <.001 258 (68.4) <.001
BMI>30 1206 (23.9) 727 (20.6) 83 (32.1) <.001 280 (31.9) <.001 116 (30.9) <.001
Medical history
Hypertension 3396 (67.5) 2226 (63.3) 196 (75.7) <.001 687 (78.2) <.001 287 (76.5) <.001
Pulse pressure (mm Hg) 57.0
48.5–67.5
55.0
47.5–66.0
57.5
50.0–68.0
.05 59.0
50.0–70.0
<.001 60.5
52.0–70.0
<.001
Unstable angina 2542 (50.3) 1725 (48.8) 129 (49.8) .75 491 (55.9) <.001 197 (52.3) .20
Myocardial infarction 2596 (52.0) 1783 (50.9) 138 (53.9) .35 452 (52.1) .51 223 (60.1) <.001
Congestive heart failure 1753 (35.0) 1136 (32.3) 91 (35.7) .27 346 (39.7) <.01 180 (48.1) <.001
PTCA 766 (15.2) 509 (14.4) 29 (11.2) .15 154 (17.6) .02 74 (19.7) .006
CABG 305 (6.0) 222 (6.3) 11 (4.3) .19 50 (5.7) .51 22 (5.8) .73
Pulmonary disease 1068 (21.2) 743 (21.1) 48 (18.6) .34 179 (20.5) .67 98 (26.1) .03
Maximum blood glucose on
admission or
preoperative, mg/dL
111.7
94.0–149.5
102.0
91.0–118.9
138.4
113.8–179.2
<.001 168.0
128.0–228.8
<.001 196.2
138.7–259.4
<.001
Additive euroSCORE 4.0
2.0–6.0
4.0
2.0–6.0
4.0
2.0–7.0
.13 4.0
2.0–6.0
.04 5.0
3.0–7.0
<.001
Medication used at admission
Aspirin 2361 (46.8) 1620 (45.8) 126 (48.7) .38 420 (47.8) .30 195 (51.7) .03
Beta–blockers 3146 (62.3) 2262 (64.0) 154 (59.5) .14 504 (57.3) <.001 226 (59.9) .12
ACE inhibitors 2066 (40.9) 1309 (37.0) 114 (44.0) .02 433 (49.3) <.001 210 (55.7) <.001
Calcium channel blockers 1690 (33.5) 1180 (33.4) 88 (34.0) .84 298 (33.9) .77 124 (32.9) .85
Steroids 75 (1.5) 51 (1.4) 3 (1.2) .71 10 (1.1) .49 11 (2.9) .03
Intravenous inotropes 188 (3.7) 121 (3.42) 8 (3.1) .77 34 (3.9) .52 25 (6.6) .002
Epinephrine 2 (0.04) 2 (0.1) 0 (0.0) >.99 0 (0.0) >.99 0 (0.0) >.99
Perioperative characteristics
Combined valve surgery 552 (10.9) 412 (11.7) 24 (9.3) .24 83 (9.44) .06 33 (8.75) .09
Assist devicek 225 (4.5) 139 (3.9) 15 (5.8) .14 40 (4.6) .40 31 (8.2) <.001
Use of epinephrine 1242 (24.6) 861 (24.4) 68 (26.3) .49 210 (23.9) .77 103 (27.3) .20
CPB time, min 96.0
74.0–124.0
95.0
73.0–123.0
99.0
77.0–125.0
.23 98.0
77.0–123.0
.14 100.0
78.0–125.0
.05
Postoperative minimum
hemoglobin,{ g/dL
9.0
8.2–10.0
9.1
8.2–10.0
9.0
8.3–9.8
.31 9.0
8.2–10.1
.87 8.9
8.1–9.8
.02
Postoperative maximum blood
glucose,# mg/dL
201.8
164.0–260.0
182.0
155.0–218.0
230.0
186.0–279.2
<.001 266.0
224.0–311.0
<.001 305.0
252.2–360.0
<.001
Postoperative creatinine  1.4 mg/dL 1669 (33.4) 1086 (31.1) 88 (34.2) .30 321 (36.8) .002 174 (46.5) <.001
Aspirin within the first 48 h after
CABG
2992 (59.3) 2122 (60.0) 145 (56.0) .20 511 (58.1) .31 214 (56.8) .22
Postoperative administration of  3
simultaneous inotropes
513 (10.2) 346 (9.8) 32 (12.4) .18 86 (9.8) .99 49 (13.0) .05
Postoperative use of epinephrine 1143 (22.6) 784 (22.2) 68 (26.3) .13 191 (21.7) .77 100 (26.5) .06
Postoperative use of steroids 286 (5.7) 204 (5.8) 12 (4.6) .45 46 (5.2) .53 24 (6.4) .64
BMI, Body mass index; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft; euroSCORE, European System for Cardiac Operative Risk
Evaluation; ACE, angiotensin-converting enzyme;DOS, day of surgery; POD, postoperative day. *Categoric variables are summarized by numbers and percentages, and P values
were calculated by the chi-square or Fisher exact test (as appropriate); continuous variables are summarized by medians and interquartile ranges, and P values were calculated by
the Wilcoxon rank-sum test. Bonferroni adjustment requires P<.016 for significance. yP values are for the comparison between nondiabetic patients and type 2 diabetic patients
with diet control. zP values are for the comparison between nondiabetic patients and type 2 diabetic patients using oral antidiabetic medication. xP values are for the comparison
between nondiabetic patients and type 1 diabetic patients, insulin treated. kInsertion of intra-aortic balloon pump or ventricular assist device or extracorporeal membrane oxy-
genation was performed preoperatively, during surgery, or on the remaining DOS. {Postoperative minimum hemoglobin was the lowest hemoglobin recorded on the remaining
DOS, POD1, POD2, or POD3. #Postoperative maximum blood glucose was the highest maximal blood glucose recorded on the remaining DOS, POD1, POD2, or POD3.
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FIGURE 1. Mortality rate and hyperglycemia in nondiabetic patients. The
nondiabetic population was divided into 15 equally sized groups according
to maximum DOS–POD3 blood glucose level. The x-axis shows the mean
maximum blood glucose values of the 15 groups. In-hospital mortality rate
and maximumDOS–POD3 blood glucose levels in the nondiabetic popula-
tion showed a strong linear relationship at blood glucose levels of 200 mg/
dL or greater. Numbers above bars indicate percent mortality. Bars indicate
standard deviation. DOS, Day of surgery; POD3, postoperative day 3.
FIGURE 2. Mortality rate and hyperglycemia in diabetic patients. The di-
abetic population was divided into 15 equally sized groups according to
maximum. DOS–POD3 blood glucose level. The x-axis shows the mean
maximum blood glucose values of the 15 groups. In the diabetic popula-
tion, only when glucose levels exceeded 300 mg/dL was there a significant
increase in unadjusted mortality compared with lower levels. Numbers
above bars indicate percent mortality. Bars indicate standard deviation.
DOS, Day of surgery; POD3, postoperative day 3.
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Mantidiabetic-controlled, and insulin-treated groups, respec-
tively. Mortality was significantly higher in the diabetic
population compared with the nondiabetic population
(4.2% vs 2.9%; P ¼ .02).
Perioperative Glycemic Control
Postoperative blood glucose measurements were avail-
able for 4799 patients. In the whole population, blood glu-
cose control was good (glucose maximum<200 mg/dL) in
2358 patients (49.1%), moderate (200–<250 mg/dL) in
1071 patients (22.3%), poor (250–<300 mg/dL) in 679 pa-
tients (14.2%), and very poor (300 mg/dL) in 691 patients
(14.4%) in the early postoperative period. In the nondia-
betic population, postoperative blood glucose control was
good in 2127 patients (64.4%), moderate in 711 patients
(21.5%), poor in 282 patients (8.5%), and very poor in
185 patients (5.6%). In the diabetic population, blood glu-
cose control was good in 231 patients (15.5%), moderate in
360 patients (24.1%), poor in 397 patients (26.6%), and
very poor in 506 patients (33.9%).
Persistent Hyperglycemia and Administration of
Insulin
Postoperatively, 831 (25.1%) of nondiabetic patientswere
treated with insulin from the DOS to POD3, in comparison
with 1261 (84.4%) of the diabetic patients (diet-controlled
type 2 diabetes: 59.2%; oral antidiabetic-controlled type 2
diabetes: 87.2%; insulin-treated diabetes: 95.2%). Stratified
analysis was performed to examine the association between
diabetes and insulin treatment, controlling for the maximum
postoperative blood glucose levels on DOS to POD3. At the
same blood glucose level, diabetic patients were more likely
to be treated with insulin (maximum glucose<200 mg/dL:
odds ratio [OR], 11.06; 95% confidence interval [CI],The Journal of Thoracic and Ca8.23–14.88; P< .001; 200–<250 mg/dL: OR, 7.19; 95%
CI, 5.37–9.62; P < .001; 250–<300 mg/dL: OR, 6.08;
95% CI, 4.13–8.94; P < .001; 300 mg/dL: OR, 5.88;
95% CI, 3.38–10.23; P<.001).
Intra- and Postoperative Hyperglycemia and
Mortality
The relationship between early postoperative maximum
blood glucose levels and mortality rate in the nondiabetic
population differed from that in the diabetic population.
In the nondiabetic population, the relationship between
maximum glucose between DOS and POD3 and mortality
rate showed a reasonably linear pattern of greater than
200 mg/dL (Figure 1). In contrast, in the diabetic popula-
tion, association with an increase in the mortality rate was
present only when postoperative maximum blood glucose
levels exceeded 300 mg/dL (Figure 2).
Stratified analysis of crude in-hospital mortality rates by
hyperglycemia, diabetes, and insulin treatment (on DOS to
POD3) status resulted in similar findings. The analysis was
repeated using different levels to define control of hypergly-
cemia: maximum blood glucose on DOS to POD3 200 mg/
dL or greater, 250 mg/dL or greater, or 300 mg/dL or greater
(Table 2). In nondiabetic patients, hyperglycemia was asso-
ciated with increased in-hospital mortality, regardless of in-
hospital insulin treatment. Although a significant difference
in unadjusted mortality was observed in diabetic patients
for maximum glucose 300 mg/dL or greater versus maxi-
mum glucose less than 300 mg/dL, this difference was not
observed in the multivariable logistic regression after ad-
justment for other independent predictors.
In the final multivariate logistic regression models, the
postoperative maximum blood glucose level remained an
independent predictor for mortality in the nondiabeticrdiovascular Surgery c Volume 142, Number 2 433
TABLE 2. In-hospital mortality rate by hyperglycemia and insulin treatment status*
No insulin
No./total of patients with in-hospital mortality
Insulin
No./total of patients with in-hospital mortality
Definition of hyperglycemia Hyperglycemia No hyperglycemia Py Hyperglycemia No Hyperglycemia Py
Maximum blood glucose 
200 mg/dL
All patients 15/804 (1.9) 15/1903 (0.8) .01 100/1637 (6.1) 10/455 (2.2) <.001
Nondiabetic patients 13/652 (2.0) 13/1822 (0.7) .006 53/526 (10.1) 5/305 (1.6) <.001
Diabetic patients 2/152 (1.3) 2/81 (2.5) .52 47/1111 (4.2) 5/150 (3.3) .60
Maximum blood glucose 
250 mg/dL
All patients 8/232 (3.4) 22/2475 (0.9) .003 80/1138 (7.0) 30/954 (3.1) <.001
Nondiabetic patients 7/164 (4.3) 19/2310 (0.8) <.001 41/303 (13.5) 17/528 (3.2) <.001
Diabetic patients 1/68 (1.5) 3/165 (1.8) .85 39/835 (4.7) 13/426 (3.1) .17
Maximum blood glucose 
300 mg/dL
All patients 2/61 (3.3) 28/2646 (1.1) .15 57/630 (9.0) 53/1462 (3.6) <.001
Nondiabetic patients 2/39 (5.1) 24/2435 (1.0) .06 28/146 (19.2) 30/685 (4.4) <.001
Diabetic patients 0/22 (0.0) 4/211 (1.9) >.99 29/484 (6.0) 23/777 (3.0) .009
*Hyperglycemia was defined on the basis of the maximum blood glucose from the remaining DOS to POD3, using different cutoff levels: maximum blood glucose 200 mg/dL,
 250 mg/dL, or 300 mg/dL; insulin treatment was defined as receiving insulin from the remaining DOS to POD3. Percentage is shown in parentheses. yP values shown are for
the comparison between patients with and without hyperglycemia.
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Mpatients. This was not the case in the diabetic population
(Table 3). Intraoperative maximum blood glucose levels
showed a significant univariate association with mortality
in nondiabetic (P ¼ .02) but not in diabetic (P ¼ .95) pa-
tients. In nondiabetic patients, intraoperative blood glucose
levels showed no independent relationship with mortality in
the multivariate model. When antifibrinolytic agents and
early postoperative aspirin were introduced into the model,
the relationship between glucose and mortality (and other
covariates in the model) remained unchanged.TABLE 3. Multivariable logistic regression analysis for in-hospital mortal
Non
Risk factor Odds ratio
Maximum blood glucose:
200–<250 vs<200 mg/dL 1.36 (0.6
250–<300 vs<200 mg/dL 2.56 (1.1
300 vs<200 mg/dL 2.74 (1.2
Additive euroSCOREy 1.09 (1.0
Preoperative pulse pressure per 10 mm Hg incrementz 1.36 (1.1
Assist devicex 2.44 (1.3
Postoperative administration of  3 simultaneous inotropes 6.42 (3.6
DOS–POD3 insulin treatment 2.04 (1.1
Postoperative creatinine  1.4 mg/dL 3.88 (2.0
DOS–POD3 hemoglobink
*CI, Confidence interval; euroSCORE, European System for Cardiac Operative Risk Evalu
population, 262 patients were excluded because of missing values for at least one of the risk
chi-square test statistic was 10.47 (P¼ .23). The C-index for the model was .90. In the mod
at least one of the risk factors in the model, including the covariates. The Hosmer–Lemes
model was .87. yORwas calculated per 1-point increment of additive euroSCORE. zORwas
of 40 mm Hg). xUse of intra-aortic balloon pump or ventricular assist device or extracorpo
kDOS–POD3 hemoglobin was categorized per quartile of the lowest hemoglobin value betw
of the hemoglobin value (DOS–POD3).
434 The Journal of Thoracic and Cardiovascular SurgRisk Factors for Hyperglycemia
In the nondiabetic population, patients with postoperative
hyperglycemia (maximum blood glucose DOS–POD3 
250 mg/dL) had more comorbidities. Preoperative blood
glucose level, European System for Cardiac Operative
Risk Evaluation risk group, impaired renal function, long
duration of CPB, need for assist devices, and need for
high inotropic support were significant independent risk
factors for hyperglycemia among nondiabetic patients
(Table 4).ity in nondiabetic and diabetic patients*
diabetic population
(n ¼ 3535)
Diabetic population
(n ¼ 1515)
(95% CI) P value Odds ratio (95% CI) P value
5–2.82) .41
8–5.57) .02
2–6.16) .01
1–1.17) .02 1.12 (1.03–1.22) .01
6–1.60) <.001
0–4.57) .006 3.87 (1.93–7.79) <.001
5–11.30) <.001 3.50 (1.86–6.57) <.001
2–3.70) .02
6–7.32) <.001 6.11 (2.66–14.02) <.001
0.69 (0.52–0.91) .009
ation; DOS, day of surgery; POD, postoperative day. In the model for the nondiabetic
factors in the model, including the covariates. The Hosmer–Lemeshow goodness-of-fit
el for the diabetic population, 18 patients were excluded because of missing values for
how goodness-of-fit chi-square test statistic was 8.82 (P ¼ .36). The C-index for the
calculated per 10 mmHg increment in preoperative pulse pressure (above a threshold
real membrane oxygenation preoperatively, during surgery, or on the remaining DOS.
een the day of surgery and the third postoperative day; ORwas calculated for quartiles
ery c August 2011
TABLE 4. Multivariable logistic regression analysis for hyperglycemia
in nondiabetic patients
Predictors Odds ratio (95% CI) P value
euroSCORE risk group* 1.35 (1.15–1.59) <.001
Maximum blood glucose
(admission or preoperative)y
1.98 (1.43–2.74) <.001
Creatinine (admission or
preoperative)  1.4 mg/dL
1.45 (1.08–1.93) .01
Intraoperative administration
of  2 simultaneous inotropes
1.61 (1.26–2.05) <.001
Assist devicez 3.21 (2.09–4.93) <.001
CPB time (min)x 1.004 (1.001–1.006) .006
CI, Confidence interval; euroSCORE, European System for Cardiac Operative Risk
Evaluation; CPB, cardiopulmonary bypass. For this analysis, 946 patients (of 3535
nondiabetic patients) were excluded because of missing values for postoperative
hyperglycemia or at least one of the predictors in the model, including the covariates.
The Hosmer–Lemeshow goodness-of-fit chi-square test statistic was 5.45 (P ¼ .71).
The C-index for the model was .69. *euroSCORE risk group: low risk, additive
euroSCORE 0–3; moderate risk, additive euroSCORE 4–7; and high risk, additive
euroSCORE  8. yOR of maximum blood glucose (admission or preoperative) was
calculated as>144mg/dL vs 144mg/dL. zUse of intra-aortic balloon pump or ven-
tricular assist device or extracorporeal membrane oxygenation preoperatively, during
surgery, or on the remaining DOS. xOR of CPB time was calculated per 1-minute
increment of CPB time.
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MDISCUSSION
In this large, international, multicenter CABG cohort, we
found that the early postoperative, but not the intraopera-
tive, maximum blood glucose level (glucose maximum
250 mg/dL) was associated with increased in-hospital
mortality. This risk was confined to nondiabetic patients.
In contrast, hyperglycemia was not associated with higher
mortality in diabetic patients after adjustment for other
variables. In nondiabetic patients, the direct relationship be-
tween mortality and the level of postoperative hyperglyce-
mia persisted regardless of in-hospital insulin treatment.
These data suggest that postoperative hyperglycemia is
a marker for mortality only in nondiabetic patients. Accord-
ingly, diabetic patients should be separately analyzed in risk
stratification.
Acute elevation of blood glucose levels has been found to
be associated with increased production of oxygen-derived
radicals, decreased complement function, and activation
of protein kinase C and nuclear factor kB.10-12 Stress
situations, such as surgery and critical illness, induce
counter-regulatory hormone release and exacerbate the
hyperglycemic state. Because cardiac surgery with CPB
produces significant surgical stress, marked elevation of
blood glucose levels has frequently been described in pa-
tients undergoing cardiac surgery.4,9,13 The stress response
is more pronounced in unstable hemodynamic conditions,
including administration of exogenous catecholamine
infusions, use of mechanical assistance devices, and
prolonged sedation and ventilation. Stress hyperglycemia
in nondiabetic patients was shown to be dependent on the
underlying glucose tolerance type, the severity of the
disease, and the highly complex interaction of counter-The Journal of Thoracic and Caregulatory hormones.13 On the other hand, the proinflamma-
tory effect of hyperglycemia can be reversed by insulin not
only in the systemic system but also in the myocardium.14
According to the recently described metabolic phenome-
non,15 persistent hyperglycemia causes cellular damage
and leads to overproduction of reactive oxygen species and
thus damages and alters the functions of other parts of the
cell, resulting in a continuous overproduction of reactive ox-
ygen species.10This oxidative stress persists over a prolonged
time, independently of the actual glycemic level, in a self-
sustaining manner.15 Experimental and clinical studies have
convincingly established the consequence of metabolic
memory, that is, the long-lasting effect of the initial occur-
rence of poor control of hyperglycemia will cause microvas-
cular complications despite termination of hyperglycemia
and reestablishment of good glycemic control later in the
treatment.16Moreover, a beneficial effect persists if goodgly-
cemic control is initiated early, even when followed by poor
glycemic control.16 According to another explanation,
chronic hyperglycemia causes cellular conditioning, such
as downregulation of glucose transporters, which might be
protective against acute hyperglycemia-mediated damage
in diabetic patients.5 In regard to our findings, we can there-
fore postulate that poor glycemic control and hyperglycemia
itself in the perioperative period caused fewer deleterious
consequences in the diabetic patients, because their metabo-
lism had previously been modulated. These hypotheses are
supported by the fact that in-hospital insulin treatment was
not associated with a decreased risk of mortality. We should
emphasize that glycemic control with intravenous insulin to
maintain serum glucose less than 180 mg/dL is recommen-
ded intraoperatively and postoperatively for at least 24 hours
or the duration of intensive care unit stay for patientswith and
without diabetes undergoing cardiac surgery.4 In single-
center studies, strict glycemic control reducedmortality in di-
abetic patients.17 Therefore, insulin infusionprotocols should
not be neglected.
Our findings are consistent with previous studies report-
ing that stress hyperglycemia was more deleterious in
patients without a history of diabetes mellitus.2,7,18
Although nondiabetic patients were shown to have even
lower median glucose values than diabetic patients, their
mortality rate was twice as high.13 Two meta-analyses for
mortality after myocardial infarction2 and a study of criti-
cally ill patients19 support the separate investigation of dia-
betic and nondiabetic populations, when maximum blood
glucose levels are included in the analysis. Recent investi-
gations have also indicated that hyperglycemia, but not
a history of diabetes, was associated with increased risk
of mortality in patients undergoing cardiac surgery9 and
in critically ill patients.20 Maximum blood glucose levels
were associated with increased risk for mortality in nondi-
abetic patients, but not in the diabetic patients.20 In addition,
diabetes is no longer considered an independent risk factorrdiovascular Surgery c Volume 142, Number 2 435
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betic patients have other in-hospital risk factors for mortal-
ity. Because diabetic patients undergoing CABG surgery
still have both worse short- and long-term survival com-
pared with nondiabetic patients,21 a tailored risk estimation
and a systematic approach for the treatment of the diabetic
population are still lacking. Our findings further confirm the
need for the separate analysis of diabetic and nondiabetic
patients in risk stratification of CABG surgery.
Considerable numbers of patients can have abnormal glu-
cose metabolism or declining glucose tolerance before the
diagnosis of overt diabetes at the time of operation or during
hospitalization. As a consequence, the diagnosis of diabetes
listed at discharge has dramatically increased. Similar to
other reports, our study found that blood glucose levels at
admission (which are not always equivalent to fasting blood
glucose values) were also an independent predictor of high
postoperative maximum blood glucose levels. Admission
blood glucose levels were associated with significant mor-
bidity after CABG surgery.22 Our analyses indicated that
there is a gradual increase in risk relative to blood glucose
levels, regardless of the administration of insulin.
Except for a reduced risk of septicemia, a meta-analysis19
and a randomized control trial23 failed to show benefits
from tight glycemic control. The occurrence of hypoglyce-
mia was significantly higher in the group under tight glyce-
mic control, and hypoglycemia was independently
associated with increased risk for mortality. These results
indicate that the goal of maintaining normoglycemia in crit-
ically ill patients did not reduce mortality but was associ-
ated with an increased risk of hypoglycemia. High blood
glucose levels during CPB were found to be independent
predictors of mortality after CABG surgery.24 The variabil-
ity and fluctuation of intraoperative and postoperative blood
glucose levels have been found to be associated with in-
creased mortality and morbidity after cardiac surgery.25
It should also be noted that comparison of the results of
published studies is difficult, because the definition of hy-
perglycemia (mean, maximum, or fluctuation of blood glu-
cose levels) and timing of blood glucose sampling vary
from one study to another. Also, the definitions of morbidity
and the investigated populations were not comparable in
most of the studies.
Limitations
Our observations have limitations inherent to the study de-
sign. First, the participating investigators in the study had no
role in the management of the enrolled patients. Second,
there were limited data available for diabetes-specific vari-
ables, for example, the amount of insulin administered and
the type of oral antidiabetic used. Only a history of diabetes
was used for patient categorization.HemoglobinA1cwas not
investigated, and preoperative blood glucose levels were
not used in the classification of diabetes status. The study436 The Journal of Thoracic and Cardiovascular Surgdid not regulate the institutional protocols for insulin treat-
ment, cardioplegia, or type of blood glucose measurement.CONCLUSIONS
Our observations strongly suggest that hyperglycemia, in
the absence of a history of diabetes, was independently as-
sociated with in-hospital mortality after CABG surgery and
that this effect was independent of in-hospital insulin treat-
ment. Postoperative hyperglycemia was not associated with
an increased risk of mortality in the diabetic population.
Our results also indicate that diabetic and nondiabetic pa-
tients should be considered separately in risk stratification.References
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APPENDIX E1
The Ischemia Research and Education Foundation (IREF) is
an independent, nonprofit foundation, formed in 1987, that
supports the development of clinical investigators using ob-
servational studies and clinical trials addressing ischemic
injury of the heart, brain, kidney, and gastrointestinal tract.
The IREF provided all funding for execution of the study,
collection of the data, and analysis and publication of the
findings. The Multicenter Study of Perioperative Ischemia
(MCSPI) Research Group, formed in 1988, is an association
of 160 international medical centers located in 23 countries,
organized through and supported by grants from the IREF.
The following institutions and persons coordinated the
MCSPI EPI-II study. Study Chairman—D. Mangano; Se-
nior Editors—J. Levin, L. Saidman; Study Design and
Analysis Center: Ischemia Research and Education
Foundation—P. Barash, C. Dietzel, A. Herskowitz, Y.
Miao, I.C. Tudor. Editorial/Administrative Group—D.
Beatty, I. Lei, B. Xavier. The following institutions and per-
sons participated in theMCSPI EPI-II Study. Centers and in-
vestigators: United States—University of Chicago, Weiss
Memorial Hospital—S. Aronson; Beth Israel Hospital—
M. Comunale; Massachusetts General—M. D’Ambra; Uni-
versity of Rochester—M. Eaton; Baystate Medical
Center—R. Engelman; Baylor College of Medicine—J.
Fitch; Duke Medical Center—K. Grichnik; UTHSCSA-
Audie Murphy VA, UTHSCSA-University Hospital—C.B.
Hantler; St. Luke’s Roosevelt Hospital—Z. Hillel; New
York University Medical Center—M. Kanchuger, J. Os-
trowski; Stanford University Medical Center—C. M. Man-
gano; Yale University School of Medicine—J. Mathew,
M. Fontes, P. Barash; University of Wisconsin—M.
McSweeney, R. Wolman; University of Arkansas for Medi-
cal Sciences—C.A. Napolitano; Discovery Alliance, Inc.—
L.A. Nesbitt; VA Medical Center, Milwaukee—N. Nijha-
wan; Texas Heart Institute, Mercy Medical Center—N.
Nussmeier; University of TexasMedical School, Houston—
E.G. Pivalizza; University of Arizona—S. Polson; Emory
University Hospital—J. Ramsay; Kaiser Foundation
Hospital—G. Roach; Thomas Jefferson University
Hospital—N. Schwann, S. McNulty, MCP Hahnemann
University Hospital—N. Schwann; VAMC Houston—S.
Shenaq; Maimonides Medical Center—K. Shevde; Mt.
Sinai Medical Center—L. Shore-Lesserson, D. Bronheim;
University of Michigan—J. Wahr; University of
Washington—B. Spiess; VA Medical Center, S.F.—A. Wal-
lace; Austria—University of Graz—H. Metzler; Canada—
University of British Columbia—D. Ansley, J.P. O’Connor;
TheTorontoHospital—D.Cheng;LavalHospital,Quebec—
D.Co^te; Health SciencesCentre-University ofManitoba—P.
Duke; University of OttawaHeart Institute—J.Y. Dupuis,M.
Hynes; University of Alberta Hospital—B. Finegan; Mon-
trealHeart Institute—R.Martineau, P.Couture; St.Michael’s
Hospital, University of Toronto—D. Mazer; Colombia—
Fundacion Clinico Shaio—J. C. Villalba, M.E. Colmenares;
France—CHRULeBocage—C.Girard; Hospital Pasteur—
C. Isetta; Germany—Universit€at W€urzburg—C.A. Greim,
N. Roewer; Universit€at Bonn—A. Hoeft; University of
Halle—R. Loeb, J. Radke; Westfalische Wilhelms-Uni-
versit€at Munster—T. Mollhoff; Universit€at Heidelberg—J.
Motsch, E. Martin; Ludwig-Maximillians Universit€at—E.
Ott; Ludwig-Maximillians Universit€at—P. Ueberfuhr
(Department of Cardiac Surgery); Universit€at Krankenhaus
Eppendorf—J. Scholz, P. Tonner; Georg-August Universit€at
G€ottingen—H. Sonntag;Hungary—Orszagos Kardiologiai
Intezet—A. Szekely; India—Escorts Heart Institute—R. Ju-
neja; Apollo Hospital—G.Mani; Israel—Hadassah Univer-
sity Hospital—B. Drenger, Y. Gozal, E. Elami; Italy—San
Raffaele Hospital, Universita de Milano—C. Tommasino;
Mexico—Instituto Nacional de Cardiologia—P. Luna; The
Netherlands—University Hospital Maastricht—P. Roekaerts,
S. DeLange; Poland—Institute of Cardiology—R. Pfitzner;
Romania—Institute of Cardiology—D. Filipescu;
Thailand—Siriraj Hospital—U. Prakanrattana; United
Kingdom—Glenfield Hospital—D.J.R. Duthie; St. Thomas’
Hospital—R.O. Feneck; The Cardiothoracic Centre,
Liverpool—M.A. Fox; South Cleveland Hospital—J.D. Park;
Southhampton General Hospital—D. Smith; Manchester
Royal Infirmary—A. Vohra; Papworth Hospital—A. Vuyl-
steke, R.D. Latimer.
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